Premium
Coherus BioSciences Inc (CHRS)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Show more
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE...
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund...
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1794 | -11.0061349693 | 1.63 | 1.75 | 1.35 | 3120152 | 1.5380695 | CS |
| 4 | 0.2256 | 18.4163265306 | 1.225 | 2.43 | 1.19 | 10006778 | 1.64625973 | CS |
| 12 | 0.4106 | 39.4807692308 | 1.04 | 2.43 | 0.6655 | 5371622 | 1.35462435 | CS |
| 26 | -0.2394 | -14.1656804734 | 1.69 | 2.43 | 0.6655 | 3532211 | 1.35506979 | CS |
| 52 | -0.5994 | -29.2390243902 | 2.05 | 3.7 | 0.6655 | 3643477 | 1.94174201 | CS |
| 156 | -16.2994 | -91.8276056338 | 17.75 | 17.92 | 0.6655 | 2493731 | 3.88105148 | CS |
| 260 | -16.8694 | -92.0818777293 | 18.32 | 23.03 | 0.6655 | 1897112 | 6.76111721 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
